VALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ HIV infection with plasma and CSF HIV RNA          │ HIV infection with plasma and CSF HIV RNA          │     100 │
│ concentrations (using Roche Amplicor assay) \>     │ concentrations (using Roche Amplicor assay) >      │         │
│ 1,000 copies/ mL (available after baseline LP)     │ 1,000 copies/ mL (available after baseline LP)     │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Off antiretroviral therapy (ART) for \> 6 weeks    │ Off antiretroviral therapy (ART) for > 6 weeks     │     100 │
│ before the study and no plans to begin treatment   │ before the study and no plans to begin treatment   │         │
│ for the study duration. (The decision of whether   │ for the study duration. (The decision of whether   │         │
│ or not a subject takes antiretroviral therapy will │ or not a subject takes antiretroviral therapy will │         │
│ be made by the subject in consultation with        │ be made by the subject in consultation with        │         │
│ his/her primary care provider prior to screening   │ his/her primary care provider prior to screening   │         │
│ for this study.)                                   │ for this study.)                                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Predicted adherence to the medication              │ Predicted adherence to the medication              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Capable of providing informed consent              │ Capable of providing informed consent              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ When available, subjects will be screened for      │ When available, subjects will be screened for      │     100 │
│ stability of blood CD4 and HIV RNA levels          │ stability of blood CD4 and HIV RNA levels          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Taking a tetracycline within 6 months or history   │ Taking a tetracycline within 6 months or history   │     100 │
│ of adverse reaction to minocycline or another      │ of adverse reaction to minocycline or another      │         │
│ tetracycline                                       │ tetracycline                                       │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Enhanced risk from lumbar puncture, including      │ Enhanced risk from lumbar puncture, including      │     100 │
│ documented or suspected cerebral mass lesion       │ documented or suspected cerebral mass lesion       │         │
│ predisposing to brain herniation or bleeding       │ predisposing to brain herniation or bleeding       │         │
│ diathesis                                          │ diathesis                                          │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnancy or expectation of pregnancy during the   │ Pregnancy or expectation of pregnancy during the   │     100 │
│ study                                              │ study                                              │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Active opportunistic infection or active           │ Active opportunistic infection or active           │     100 │
│ neurological disease that might confound           │ neurological disease that might confound           │         │
│ evaluation                                         │ evaluation                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ BUN or creatine above the normal limits            │ BUN or creatine above the normal limits            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Taking other drugs known to reduce the metabolism  │ Taking other drugs known to reduce the metabolism  │     100 │
│ of minocycline and thus increase the probability   │ of minocycline and thus increase the probability   │         │
│ of toxicity                                        │ of toxicity                                        │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ ADC Stage \> 1                                     │ ADC Stage > 1                                      │      96 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ \> 18 years old                                    │ > 18 years old                                     │      97 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Hemoglobin \< 10 Gms/dL                            │ Hemoglobin < 10 Gms/dL                             │      98 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ CD4 cell counts \>150 cells/μL (though likely      │ CD4 cell counts >150 cells/μL (though likely most, │      99 │
│ most, if not all, will be \>250 cells/μL)          │ if not all, will be >250 cells/μL)                 │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒═══════════════════════════════════╤═══════════════════════════════════════╤═════════╕
│ Personal Criteria                 │ CHIA Criteria                         │   Score │
╞═══════════════════════════════════╪═══════════════════════════════════════╪═════════╡
│ Must have minimum age of 18 Years │ Predicted adherence to the medication │      34 │
╘═══════════════════════════════════╧═══════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 98
Average Levenshtein Ratio of individual lines: 95.25
OverAll Ratio: 96.625
